# Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)

> **NCT07290257** · PHASE4 · RECRUITING · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Alagille Syndrome

## Interventions

- **DRUG:** Livmarli Oral Product

## Key facts

- **NCT ID:** NCT07290257
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2030-09-22
- **Final completion:** 2030-12-22
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290257, "Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)". Retrieved via AI Analytics 2026-07-22 from https://api.ai-analytics.org/clinical/NCT07290257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*